Brief: Bone Therapeutics’ ALLOB Meets Primary Endpoints In Phase IIa Study

Biosenic SA

13/06/2019 06:18

June 13 (Reuters) - BONE THERAPEUTICS SA  BOTHE.BR :
    * REG-BONE THERAPEUTICS’ ALLOGENEIC CELL THERAPY PRODUCT, ALLOB, MEETS PRIMARY ENDPOINTS IN
PHASE
IIA STUDY IN PATIENTS UNDERGOING A LUMBAR SPINAL FUSION PROCEDURE
    * TREATMENT WITH ALLOB WAS WELL-TOLERATED, CONSISTENT WITH PREVIOUS REPORTED RESULTS
    * AT 12 MONTHS 73.3% OF PATIENTS SHOWED SUCCESSFUL FUSION AND 86.7% AT 24 MONTHS
    * TREATMENT WITH ALLOB RESULTED IN SIGNIFICANT CLINICAL AND RADIOLOGICAL IMPROVEMENTS
    * CONFIRMATION OF BROAD POTENTIAL OF ALLOB TO SIGNIFICANTLY IMPROVE TREATMENT OPTIONS IN
ORTHOPAEDICS AND BONE DISEASES

Source text for Eikon:  ID:nGNEc4Nvj4 
Further company coverage:  BOTHE.BR 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))